Abstract 966P
Background
Hepatocellular carcinoma (HCC) represents the third most deadly cancer worldwide with still high therapeutic failure and recurrence rates mainly associated with the late diagnosis and the molecular heterogeneity of this liver tumor. The transmembrane glycoprotein neuropilin-1 (NRP1) has shown a key role in the modulation of tumor-associated signaling pathways and processes by interacting with key receptor tyrosine kinases. Nonetheless, few studies have evaluated the potential value of NRP1 as a tumor biomarker or therapeutic target in HCC. For this reason, we aimed at assessing the clinical significance of the receptor NRP1 in the prognosis, diagnosis and other tumor-associated features in HCC patients.
Methods
We conducted a systematic review with meta-analysis including all the articles published up to May 31st 2022 that evaluated the clinical correlation of NRP1 overexpression with tumor prognosis, development and/or other clinicopathological features in patients diagnosed with HCC. An exhaustive literature search was performed in five online databases, selecting potential papers to be included based on predefined eligibility criteria. Data from included studies were extracted or estimated by Parmar method and meta-analyzed employing the STATA 16 software.
Results
A total of 1305 patients from seven studies were included in the quantitative analysis, showing approximately 53.81% of patients NRP1 overexpression. After meta-analysis, higher levels of NRP1 proved to be significantly correlated to poor prognosis, represented by lower overall survival (OS). Moreover, a significant association with tumor pathogenesis was also found by observing higher NRP1 expression in tumor tissue samples from 692 HCC patients. Finally, a marked correlation was obtained between increased NRP1 expression and patient’s age, younger than 50 years old, and a higher risk of venous invasion, highlighting the potential of NRP1 as a tumor biomarker in HCC.
Conclusions
Overall, these results suggest that NRP1 have a potential role for prognosis, development and risk of invasion, and, therefore, could constitute a valuable biomarker in patients diagnosed with HCC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
CIBERehd is funded by Instituto de Salud Carlos III (ISCIII), Spain.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
832P - Characterisation of EXS73565: A potent and selective MALT1 inhibitor with low drug-drug interaction risk and potential in lymphoma
Presenter: Major Gooyit
Session: Poster session 18
833P - New targets for adult T cell leukemia/lymphoma (ATLL): A map for ATLL immunotherapy
Presenter: Zahra Rezaei Borojerdi
Session: Poster session 18
834P - Phase II clinical study of VR-CAP regimen for first-line treatment of marginal zone lymphoma
Presenter: Junfeng Chu
Session: Poster session 18
835P - A safe and effective immunochemotherapy with oral sobuzoxane and etoposide for untreated diffuse large B cell lymphoma patients aged 80 and over
Presenter: Kaname Miyashita
Session: Poster session 18
838P - Matching-adjusted indirect comparison (MAIC) of axicabtagene ciloleucel (axi-cel) and epcoritamab (epcor) in relapsed/refractory (R/R) large B cell lymphoma (LBCL) after at least two prior systemic therapies (3L+)
Presenter: Olalekan Oluwole
Session: Poster session 18
840P - Genomic landscape, immune characteristics and prognostic mutation signature of extranodal NK/T cell lymphoma, nasal type in China
Presenter: Yue Chai
Session: Poster session 18
841P - Ki67-revised risk index to risk-stratify patients with extra-nodal natural killer/T cell lymphoma
Presenter: Shuo Li
Session: Poster session 18